skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone

Original Research

(2853) Views  (724) Full article downloads

Authors: Hong Liu-Seifert, Bruce J Kinon, Christopher J Tennant, Jennifer Sniadecki, Jan Volavka

Published Date January 2009 Volume 2009:5 Pages 47 - 54
DOI: http://dx.doi.org/10.2147/NDT.S4766

Hong Liu-Seifert1, Bruce J Kinon1, Christopher J Tennant2, Jennifer Sniadecki1, Jan Volavka3

1Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA; 2CJT Biomedical Consulting, South Lake Tahoe, CA, USA; 3New York University, New York, NY, USA

Objective: To better understand sexual dysfunction in patients with schizophrenia and its associations with prolactin and reproductive hormones.

Methods: This was a secondary analysis of an open-label, one-day study (N = 402). The primary objective of the study was to assess the prevalence of hyperprolactinemia in patients with schizophrenia who had been treated with conventional antipsychotics or risperidone. Other atypical antipsychotics available at the time of the study were not included due to a more favorable prolactin profile.

Results: The majority of patients (59% of females and 60% of males) reported impairment of sexual function. In postmenopausal females, risk of impaired sexual interest was increased by 31% for every 10 ng/ml increase in prolactin (p = 0.035). In males, lower testosterone was associated with higher prolactin (p < 0.001) and with orgasmic (p = 0.004) and ejaculatory dysfunction (p = 0.028).

Conclusion: These findings suggest that hyperprolactinemia may be associated with sexual dysfunction. They also provide more information on the relationships between prolactin, reproductive hormones, and sexual dysfunction. Sexual dysfunction is an understudied yet important consideration in the treatment of schizophrenia. More attention is warranted in this area as it may provide opportunities for improved quality of life and adherence to treatment for patients.

Keywords: sexual dysfunction, schizophrenia, hyperprolactinemia, antipsychotics, risperidone








Readers of this article also read:

Combination therapy or monotherapy for the depressed type of schizoaffective disorder
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The pathophysiology of bronchiectasis
New atypical antipsychotics for schizophrenia: iloperidone
Health literacy and health seeking behavior among older men in a middle-income nation
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Zinc oxide nanoparticles as selective killers of proliferating cells
Antioxidant oils and Salmonella enterica Typhimurium reduce tumor in an experimental model of hepatic metastasis
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy